This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Kiora Pharmaceuticals (KPRX) and MAIA Biotechnology, Inc. (MAIA)

Tipranks - Tipranks - Tue Jun 23, 8:50AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Exelixis (EXEL), Kiora Pharmaceuticals (KPRX) and MAIA Biotechnology, Inc. (MAIA) with bullish sentiments.

TipRanks' Prime Week Sale - 70% Off

Exelixis (EXEL)

In a report released today, Andy Hsieh from William Blair reiterated a Buy rating on Exelixis. The company’s shares closed last Monday at $51.82.

According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 8.0% and a 43.9% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Aardvark Therapeutics, Inc., and Corbus Pharmaceuticals. ;'>

Exelixis has an analyst consensus of Moderate Buy, with a price target consensus of $48.11.

See the top stocks recommended by analysts >>

Kiora Pharmaceuticals (KPRX)

In a report released today, Michael Okunewitch from Maxim Group maintained a Buy rating on Kiora Pharmaceuticals, with a price target of $12.00. The company’s shares closed last Thursday at $2.53.

According to TipRanks.com, Okunewitch is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.9% and a 36.3% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, Rani Therapeutics Holdings, and Acrivon Therapeutics, Inc. ;'>

Currently, the analyst consensus on Kiora Pharmaceuticals is a Moderate Buy with an average price target of $12.00.

MAIA Biotechnology, Inc. (MAIA)

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc., with a price target of $14.00. The company’s shares closed last Thursday at $1.40.

According to TipRanks.com, LeBoyer is ranked 0 out of 5 stars with an average return of -10.5% and a 28.9% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Cadrenal Therapeutics, Inc., and Eledon Pharmaceuticals. ;'>

Currently, the analyst consensus on MAIA Biotechnology, Inc. is a Moderate Buy with an average price target of $14.00.

Read More on EXEL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).